-
Je něco špatně v tomto záznamu ?
Circulating Cell-Free DNA-Based Methylation Pattern in Saliva for Early Diagnosis of Head and Neck Cancer
N. Birknerova, V. Mancikova, ED. Paul, J. Matyasovsky, P. Cekan, V. Palicka, H. Parova
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
36230805
DOI
10.3390/cancers14194882
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Head and neck cancer (HNC) remains one of the leading causes of mortality worldwide due to tumor diagnosis at a late stage, loco-regional aggression, and distant metastases. A standardized diagnostic procedure for HNC is a tissue biopsy that cannot faithfully portray the in-depth tumor dynamics. Therefore, there is an urgent need to develop simple, accurate, and non-invasive methods for cancer detection and follow-up. A saliva-based liquid biopsy allows convenient, non-invasive, and painless collection of high volumes of this biofluid, with the possibility of repetitive sampling, all enabling real-time monitoring of the disease. No approved clinical test for HNC has yet been established. However, epigenetic changes in saliva circulating cell-free DNA (cfDNA) have the potential for a wide range of clinical applications. Therefore, the aim of this review is to present an overview of cfDNA-based methylation patterns in saliva for early detection of HNC, with particular attention to circulating tumor DNA (ctDNA). Due to advancements in isolation and detection technologies, as well as next- and third-generation sequencing, recent data suggest that salivary biomarkers may be successfully applied for early detection of HNC in the future, but large prospective clinical trials are still warranted.
MultiplexDX Inc One Research Court Suite 450 Rockville MD 20850 USA
MultiplexDX s r o Comenius University Science Park Ilkovicova 8 84104 Bratislava Slovakia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031602
- 003
- CZ-PrNML
- 005
- 20231116141120.0
- 007
- ta
- 008
- 230119s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers14194882 $2 doi
- 035 __
- $a (PubMed)36230805
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Birknerova, Natalia $u Department of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove and University Hospital, Charles University, 50005 Hradec Kralove, Czech Republic $u MultiplexDX s.r.o., Comenius University Science Park, Ilkovicova 8, 84104 Bratislava, Slovakia $u MultiplexDX Inc., One Research Court, Suite 450, Rockville, MD 20850, USA $1 https://orcid.org/0000000220066694
- 245 10
- $a Circulating Cell-Free DNA-Based Methylation Pattern in Saliva for Early Diagnosis of Head and Neck Cancer / $c N. Birknerova, V. Mancikova, ED. Paul, J. Matyasovsky, P. Cekan, V. Palicka, H. Parova
- 520 9_
- $a Head and neck cancer (HNC) remains one of the leading causes of mortality worldwide due to tumor diagnosis at a late stage, loco-regional aggression, and distant metastases. A standardized diagnostic procedure for HNC is a tissue biopsy that cannot faithfully portray the in-depth tumor dynamics. Therefore, there is an urgent need to develop simple, accurate, and non-invasive methods for cancer detection and follow-up. A saliva-based liquid biopsy allows convenient, non-invasive, and painless collection of high volumes of this biofluid, with the possibility of repetitive sampling, all enabling real-time monitoring of the disease. No approved clinical test for HNC has yet been established. However, epigenetic changes in saliva circulating cell-free DNA (cfDNA) have the potential for a wide range of clinical applications. Therefore, the aim of this review is to present an overview of cfDNA-based methylation patterns in saliva for early detection of HNC, with particular attention to circulating tumor DNA (ctDNA). Due to advancements in isolation and detection technologies, as well as next- and third-generation sequencing, recent data suggest that salivary biomarkers may be successfully applied for early detection of HNC in the future, but large prospective clinical trials are still warranted.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Mancikova, Veronika $u MultiplexDX s.r.o., Comenius University Science Park, Ilkovicova 8, 84104 Bratislava, Slovakia $u MultiplexDX Inc., One Research Court, Suite 450, Rockville, MD 20850, USA
- 700 1_
- $a Paul, Evan David $u MultiplexDX s.r.o., Comenius University Science Park, Ilkovicova 8, 84104 Bratislava, Slovakia $u MultiplexDX Inc., One Research Court, Suite 450, Rockville, MD 20850, USA $1 https://orcid.org/0000000270118050
- 700 1_
- $a Matyasovsky, Jan $u MultiplexDX s.r.o., Comenius University Science Park, Ilkovicova 8, 84104 Bratislava, Slovakia $u MultiplexDX Inc., One Research Court, Suite 450, Rockville, MD 20850, USA $1 https://orcid.org/0000000191550224
- 700 1_
- $a Cekan, Pavol $u MultiplexDX s.r.o., Comenius University Science Park, Ilkovicova 8, 84104 Bratislava, Slovakia $u MultiplexDX Inc., One Research Court, Suite 450, Rockville, MD 20850, USA $1 https://orcid.org/0000000188069958
- 700 1_
- $a Palicka, Vladimir $u Department of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove and University Hospital, Charles University, 50005 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000172361647
- 700 1_
- $a Párová, Helena $u Department of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove and University Hospital, Charles University, 50005 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000150404140 $7 xx0310039
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 19 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36230805 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20231116141115 $b ABA008
- 999 __
- $a ok $b bmc $g 1889567 $s 1182935
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 14 $c 19 $e 20221006 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- LZP __
- $a Pubmed-20230119